| ACE | Angiotensin-converting enzyme |
| ACE2 | Angiotensin-converting enzyme 2 |
| ACPA | Anti-citrullinated peptide antibody |
| APC | Antigen presenting cell |
| bDMARDs | Biological disease-modifying antirheumatic drugs, |
| BMD | Bone marrow density |
| COVID-19 | Coronavirus disease 2019 |
| CRP | C reactive protein |
| csDMARDs | Conventional synthetic disease-modifying antirheumatic drugs |
| FABP | Fatty-acid-binding protein |
| FCN | Ficolin |
| FOLR | Folate receptor |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor |
| IFN | Interferon |
| IL | Interleukin |
| JAK | Janus tyrosine kinase |
| LYVE | Lymphaticvessel hyaluronan receptor |
| NF-κB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| NSAID | Non-steroidal anti-inflammatory drug |
| RA | Rheumatoid arthritis |
| SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 |
| Th cells | T helper cells |
| TNF | Tumor necrosis factor |
| tsDMARDs | Targeted synthetic disease-modifying anti-rheumatic drugs |
| VEGF | Vascular endothelial growth factor |